Literature DB >> 16581272

Mixtures of glucosamine and chondroitin sulfate reverse fibronectin fragment mediated damage to cartilage more effectively than either agent alone.

G A Homandberg1, D Guo, L M Ray, L Ding.   

Abstract

OBJECTIVE: To test the effectiveness of glucosamine (GluNH(2))-HCl, chondroitin sulfate (CS) and mixtures in protecting cartilage exposed to fibronectin fragments (Fn-fs), an exposure known to enhance catabolic cytokines and matrix metalloproteinases (MMPs).
METHODS: Pharmacologic formulations of GluNH(2) (FCHG49) and CS (TRH122) (Nutramax Laboratories, Inc.) were added at 1, 10 or 100 microg/ml singly or in mixtures to bovine cartilage cultures in serum or serum-free conditions with or without Fn-f. Proteoglycan (PG) release into media and remaining cartilage PG content were measured by dye binding analysis and effects on PG synthesis by assays of 35-sulfate incorporation. Effects on MMP-3 and -13 expression were measured by Western blotting of conditioned media.
RESULTS: In serum-free conditions, the agents singly or as mixtures did not block Fn-f mediated matrix degradation. In serum, single agents were weakly effective at 100 microg/ml, while the mixture of each agent at 0.1 microg/ml decreased PG loss by about 50% by day 7 and at 1 microg/ml restored nearly 50% of the PG after 7 days in Fn-f pretreated cartilage. However, both agents singly and as mixtures at 0.1-100 microg/ml decreased MMP release. In serum, the single agents at 1-10 microg/ml weakly reversed Fn-f mediated PG synthesis suppression, while the mixtures were 100% effective at 1 microg/ml.
CONCLUSIONS: GluNH(2) and CS act synergistically in reversing damage and promoting repair at concentrations found in plasma after oral ingestion of these agents. Reversal of PG synthesis suppression correlates more with these activities than suppression of MMP-3 or -13 expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581272     DOI: 10.1016/j.joca.2006.02.003

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  7 in total

Review 1.  Fibronectin in tissue regeneration: timely disassembly of the scaffold is necessary to complete the build.

Authors:  Josephine M J Stoffels; Chao Zhao; Wia Baron
Journal:  Cell Mol Life Sci       Date:  2013-06-12       Impact factor: 9.261

2.  Anti-Inflammatory Effect of Carprofen Is Enhanced by Avocado/Soybean Unsaponifiables, Glucosamine and Chondroitin Sulfate Combination in Chondrocyte Microcarrier Spinner Culture.

Authors:  Mark W Grzanna; Erica J Secor; Lowella V Fortuno; Angela Y Au; Carmelita G Frondoza
Journal:  Cartilage       Date:  2018-06-25       Impact factor: 4.634

3.  Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?

Authors:  Eric W Orlowsky; Thomas V Stabler; Eulàlia Montell; Josep Vergés; Virginia Byers Kraus
Journal:  BMC Musculoskelet Disord       Date:  2014-09-27       Impact factor: 2.362

4.  A Comparative Study of Fibronectin Cleavage by MMP-1, -3, -13, and -14.

Authors:  Xiaorong Zhang; Christopher T Chen; Madhu Bhargava; Peter A Torzilli
Journal:  Cartilage       Date:  2012-07       Impact factor: 4.634

5.  Genetic abrogation of the fibronectin-α5β1 integrin interaction in articular cartilage aggravates osteoarthritis in mice.

Authors:  Maylin Almonte-Becerril; Irene Gimeno-LLuch; Olga Villarroya; María Benito-Jardón; Juan Bautista Kouri; Mercedes Costell
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

6.  Carprofen inhibits the release of matrix metalloproteinases 1, 3, and 13 in the secretome of an explant model of articular cartilage stimulated with interleukin 1β.

Authors:  Adam Williams; Julia R Smith; David Allaway; Pat Harris; Susan Liddell; Ali Mobasheri
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

7.  Chondroitin Sulfate Inhibits Monocyte Chemoattractant Protein-1 Release From 3T3-L1 Adipocytes: A New Treatment Opportunity for Obesity-Related Inflammation?

Authors:  Thomas V Stabler; Eulàlia Montell; Josep Vergés; Janet L Huebner; Virginia Byers Kraus
Journal:  Biomark Insights       Date:  2017-08-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.